← FDA DRUG APPROVALS

FDA ANDA · ANDA214242

MESALAMINE

Sponsor: ALKEM LABS LTD

APPLICATION
ANDA214242
TYPE
ANDA
ORIGINAL APPROVAL
2021-07-15
LATEST ACTION
2024-10-24
ROUTE
ORAL
DOSAGE FORM
CAPSULE, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

MESALAMINEPrescription
MESALAMINE 375MG · CAPSULE, EXTENDED RELEASE · ORAL

Approval history

2024-10-24Labeling · Supplement 8 · standardAP
2024-04-04Labeling · Supplement 3 · standardAP
2022-06-03Labeling · Supplement 1 · standardAP
2021-07-15UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →